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Transcatheter versus surgical aortic valve replacement in 
patients with severe aortic stenosis at low and intermediate 
risk: systematic review and meta-analysis
Reed A Siemieniuk,1,2 Thomas Agoritsas,1,3 Veena Manja,1,4,5 Tahira Devji,1 Yaping Chang,1 
Malgorzata M Bala,6 Lehana Thabane,1 Gordon H Guyatt1 
ABSTRACT
ObjeCtive
To examine the effect of transcatheter aortic valve 
implantation (TAVI) versus surgical replacement of an 
aortic valve (SAVR) in patients with severe aortic 
stenosis at low and intermediate risk of perioperative 
death.
Design
Systematic review and meta-analysis.
Data sOurCes
Medline, Embase, and Cochrane CENTRAL.
stuDy seleCtiOn
Randomized trials of TAVI compared with SAVR in 
patients with a mean perioperative risk of death <8%.
review methODs
Two reviewers independently extracted data and 
assessed risk of bias for outcomes important to 
patients that were selected a priori by a parallel 
guideline committee, including patient advisors. We 
used the GRADE system was used to quantify absolute 
effects and quality of evidence.
results
4 trials with 3179 patients and a median follow-up of 
two years were included. Compared with SAVR, 
transfemoral TAVI was associated with reduced 
mortality (risk difference per 1000 patients: −30, 95% 
confidence interval −49 to −8, moderate certainty), 
stroke (−20, −37 to 1, moderate certainty), life 
threatening bleeding (−252, −293 to −190, high 
certainty), atrial fibrillation (−178, −150 to −203, 
moderate certainty), and acute kidney injury (−53, −39 
to −62, high certainty) but increased short term aortic 
valve reintervention (7, 1 to 21, moderate certainty), 
permanent pacemaker insertion (134, 16 to 382, 
moderate certainty), and moderate or severe 
symptoms of heart failure (18, 5 to 34, moderate 
certainty). Compared with SAVR, transapical TAVI was 
associated higher mortality (57, −16 to 153, moderate 
certainty, P=0.015 for interaction between transfemoral 
versus transapical TAVI) and stroke (45, −2 to 125, 
moderate certainty, interaction P=0.012). No study 
reported long term follow-up, which is particularly 
important for structural valve deterioration.
COnClusiOns
Many patients, particularly those who have a shorter 
life expectancy or place a lower value on the risk of 
long term valve degeneration, are likely to perceive net 
benefit with transfemoral TAVI versus SAVR. SAVR, 
however, performs better than transapical TAVI, which 
is of interest to patients who are not candidates for 
transfemoral TAVI.
systematiC review registratiOn
PROSPERO CRD42016042879.
Introduction
Severe symptomatic aortic stenosis is common and, 
without aortic valve replacement, results in a life expec-
tancy of less than three years.1  Each year in the United 
States, about 75 000 patients undergo surgical aortic 
valve replacements (SAVR).2  Because aortic stenosis 
increases with age, this number will increase with the 
evolving population demographic.3
Transcatheter aortic valve implantation (TAVI) is an 
increasingly popular alternative to SAVR, at least in part 
because it does not require thoracotomy.4  Current prac-
tice guidelines recommend either TAVI or SAVR in 
patients at high surgical risk, defined as a Society of 
Thoracic Surgeons predicted risk of mortality (STS-
PROM) score of 8% or less, but recommend SAVR over 
TAVI for lower risk patients.5 6  Despite this recommen-
dation, half of the TAVI centers in Europe perform TAVI 
in intermediate risk patients (STS-PROM 4-8%) and 10% 
of centers do so in low risk patients (risk score <4%).7
The PARTNER 2A trial compared TAVI with SAVR in 
intermediate risk patients (risk score 4-8% or <4% with 
coexisting conditions that are not represented in the 
STS-PROM model).8  The authors claimed non- 
inferiority for TAVI versus SAVR for the primary com-
posite endpoint of death from any cause or disabling 
stroke at two years. Two recent meta-analyses that 
included patients from PARTNER 2A suggested that 
compared with SAVR, TAVI was associated with 
reduced odds of major bleeding, acute kidney injury, 
and new onset atrial fibrillation and with increased 
risks of pacemaker implantation, vascular complica-
tions, and aortic  regurgitation.9 10  The reviews did not, 
however, address the durability of valves and need for 
WhAT IS AlReAdy knoWn on ThIS TopIC
Surgical aortic valve replacement (SAVR) is more invasive than transcatheter aortic 
valve replacement (TAVI)
TAVI is preferred over SAVR for patients at high or extreme surgical risk
WhAT ThIS STudy AddS
Success with TAVI relative to SAVR depends on the approach: transfemoral TAVI 
probably reduces risk of death and stroke while transapical TAVI can increase 
these risks
TAVI results in a 6% increased risk of symptoms of heart failure and 1% increase in 
valve reinterventions at two years
Long term outcomes remain uncertain
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aortic  reintervention after TAVI.9 10 Moreover, the 
reviews failed to formally rate either the quality of the 
evidence or the credibility of subgroup analyses (leav-
ing the credibility of findings uncertain) or provide 
absolute risks, crucial for trading off the desirable and 
undesirable aspects of TAVI versus SAVR.
The limitations of the prior review prompted us to 
perform an updated systematic review and meta-analy-
sis of randomized controlled trials of TAVI compared 
with SAVR for patients at low and intermediate surgical 
risk. We conducted this systematic review to inform rec-
ommendations11 for the first in a new series in The BMJ 
of trustworthy recommendations published in response 
to potentially practice changing evidence,12  so called 
Rapid Recommendations. Our review complements a 
co-published meta-analysis of observational data on 
baseline risk to inform absolute effects13  and a system-
atic review on patients’ values and preferences to 
inform the relative importance of outcomes (box 1).14
Methods
Protocol
The registered study protocol is available on PROSPERO 
(CRD42016042879).15
information sources
A search from a previous systematic review that we 
judged as comprehensive included articles up to 15 July 
2012.16  We complemented that review with a search of 
Medline, Medline in-process, Embase, and Cochrane 
CENTRAL from 1 January 2012 to 12 May 2016 using a 
combination of keywords and MeSH terms for “aortic 
stenosis” AND “valve replacement”, using the sensitive 
search filters for therapeutic interventions developed 
by the Health Information Research Unit at McMaster 
University (appendix 1).17 18 There were no restrictions 
on language or publication type. We also searched all 
references from included studies and studies citing the 
included studies on Google Scholar.
study selection
We included randomized controlled trials comparing 
TAVI and SAVR in patients with severe aortic stenosis 
and a mean risk score of 8% or less. All titles and 
abstracts were screened in duplicate with the Covi-
dence online service (Alfred Health, Melbourne, Austra-
lia). If either reviewer judged that the study could meet 
the inclusion criteria, we assessed eligibility in dupli-
cate using the full text.
Data collection process
Two reviewers independently abstracted data and 
resolved conflicts by discussion. When possible, we 
analyzed patients in groups to which they were ran-
domized and from the as treated population when 
intention to treat data were not available.
summary measures and patient involvement
The outcomes chosen in this research paper were influ-
enced by two people with experience of living with aor-
tic stenosis. It was part of a wider project and is 
published in the Rapid Recommendation series explor-
ing TAVI versus SAVR for people with severe aortic ste-
nosis.11  The two patients worked with the panel to list 
the outcomes that were important to them; they identi-
fied several outcomes that other panel members had 
identified and also uniquely highlighted pain and 
recovery time as critical to decision making. We were 
not able to find direct evidence for those outcomes in 
the randomized controlled trials. All outcomes are con-
sistent with the Valve Academic Research Consortium 
(VARC)-2 standardized endpoint definitions.19
risk of bias and quality of evidence
We assessed risk of bias in duplicate with a modified 
Cochrane tool;20 reviewers resolved conflicts through 
consensus. With respect to missing data, we judged 
individual trials at high risk of bias if data from more 
than 10% of patients were unavailable.
We rated the certainty in the evidence informing 
absolute effects using the GRADE approach.21 22  All 
authors, in consultation with the parallel Rapid Recom-
mendations guidelines panel,11  participated in and 
came to consensus regarding certainty of estimates rat-
ings. The GRADE risk of bias assessment included plau-
sible worst case sensitivity analyses addressing missing 
follow-up data.23
synthesis of results
For dichotomous outcomes we conducted a random 
effects meta-analysis using both Hartung-Knapp- Sidik-
Jonkman (HKSJ) 95% confidence intervals and 
DerSimonian and Laird confidence intervals of relative 
risks and chose between the two for the primary report 
based on plausibility of results.24 We intended to pool 
continuous outcomes with mean differences with a 
similar statistical approach. We present the DerSimonian 
and Laird confidence intervals for all dichotomous and 
continuous outcomes because the other confidence 
intervals were implausibly wide in 15 of the 70 (21.4%) 
analyses (95% confidence interval of the relative effect 
>50 or <0.02) and implausibly narrow in two.
For symptoms of heart failure, we used ordinal 
regression to estimate an odds ratio across the New 
York Heart Association (NYHA) scores for each study at 
box 1: linked articles in this BMJ rapid recommendations cluster
•	Foroutan F, Guyatt GH, O’Brien K, et al. Prognosis after surgical replacement with 
a bioprosthetic aortic valve in patients with severe symptomatic aortic stenosis: 
systematic review of observational studies. BMJ 2016;354:i5065. doi:10.1136/bmj.i5065
•	Lytvyn L, Guyatt GH, Manja V, et al. Patient values and preferences on transcatheter 
or surgical aortic valve replacement therapy for aortic stenosis: a systematic review. 
BMJ Open 2016;6:e014327. doi:10.1136/bmjopen-2016-014327
•	Vandvik PO, Otto CM, Siemieniuk RA, et al. Transcatheter or surgical aortic valve 
replacement for patients with severe, symptomatic, aortic stenosis at low to 
intermediate surgical risk: a clinical practice guideline. BMJ 2016;354:i5085. 
doi:10.1136/bmj.i5085
– summary of the results from the Rapid Recommendation process
•	Magic App (www.magicapp.org)
– expanded version of the results with multilayered recommendations, evidence 
summaries, and decision aids for use on all devices
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the longest follow-up. We then pooled the odds ratios 
with random effects, weighted by inverse variance. We 
assumed and tested the proportional odds across NYHA 
classes for each individual study, using likelihood ratio 
tests. In this analysis, odds ratios can be interpreted as 
the odds of having a 1 point increase in NYHA class.
When available, we digitized Kaplan-Meier curves 
and extracted patient level data on time to event;25 we 
took this approach for mortality. We checked the pro-
portional hazards assumption and then fitted a Cox 
regression model with the study as a random effects 
(shared frailty) variable and report hazard ratios with 
confidence intervals. Sensitivity analyses were per-
formed with random effects pooling of the hazard ratios 
reported in individual studies and by pooling dichoto-
mous data at the prespecified timepoints of one month 
and one year.
We explored effect modification for four variables: 
transfemoral versus transapical approach, balloon 
expandable versus self expanding valve, higher periop-
erative risk (mean risk score ≥6%) versus lower (<6%), 
and high versus low risk of bias for each risk of bias cri-
terion. We expected that trials would have outcomes 
more favorable to TAVI than SAVR if they used a trans-
femoral approach, balloon expandable valves, and 
enrolled patients with higher perioperative risk. Sub-
group analyses were performed only if there were at 
least two randomized controlled trials in each subgroup 
or a trial’s report permitted a comparison within the 
trial (for example, the trial reported results separately 
for patients with lower versus higher risk). We com-
pared the summary estimates from each subgroup with 
binary, continuous, or ordinal data with a fixed effect 
comparison between subgroups, except when a within 
study subgroup was reported. In those situations, we 
performed two level mixed effects regression with ran-
dom effects at the study level. For subgroup analyses of 
time to event data with extracted patient level and 
within trial subgroup data available, we used a shared 
frailty Cox model with random effects at the study level. 
All primary analyses were performed with STATA v13 
(StataCorp, College Station, TX).
To calculate absolute effect estimates, we applied the 
relative effects from this review to the best estimates of 
baseline risk. Baseline risk estimates were derived from 
a systematic review of observational studies of SAVR 
conducted in parallel with this review for mortality and 
length of hospital stay.13 We used the baseline risk from 
the SAVR arms of the randomized controlled trials for 
the other outcomes.
Results
We screened 2734 unique citations, of which 55 were 
judged potentially eligible during screening of titles 
and abstracts and four were deemed eligible on full text 
review (fig 1 ). The four randomized controlled trials, all 
published after 2012, included 3179 patients: two trials 
took place in North America8 26  and two in Europe.27 28 
We included additional data published in five second-
ary reports.29-33  Most patients were men (54%) and most 
were aged over 80 (table 1 ; appendix 2 provides addi-
tional study characteristics). One study included 
patients with a mean risk score of 7.4% but required 
patients with scores <8% to have additional comorbid-
ites not included in the STS-PROM calculator.26
Two studies used a percutaneous retrograde 
approach (transfemoral),26 28  one study used a transapi-
cal approach,27  and one study used both but stratified 
randomization based on the heart team’s preferred 
approach (direct aortic approach was grouped with the 
transapical approach).8 Across all studies, 94.4% 
(n=1222) of the patients who underwent percutaneous 
retrograde TAVI had transfemoral access and 5.6% 
(n=72) had trans-subclavian access; 77.1% (n=209) of 
the patients who underwent non-percutaneous TAVI 
had transapical access and 29% (n=62) had the direct 
aortic approach.
assessment of risk of bias
All four trials were at low risk of bias for allocation con-
cealment; none blinded patients, healthcare practi-
tioners, or data collectors, and only one attempted to 
blind outcome assessors8  (appendix 3). One study 
blinded data analysts; this study, however, had a 
greater degree of missing data than other studies.26  The 
TAVI valve industry funded three studies.8 26 28 All out-
comes favoring TAVI, or transfemoral TAVI, over SAVR 
were robust to worst plausible sensitivity analyses.
Table 2 summarizes findings for all outcomes. Age 
stratified interactive summary of findings tables are 
available online at https://www.magicapp.org/public/
guideline/aEeKpL. Appendix 4 reports abstracted out-
come data by study arm.
Outcomes favoring transfemoral but not transapical 
tavi over savr
Mortality
At the longest follow-up (median two years), 319 of the 
1578 (20.2%) patients undergoing TAVI and 340 of 1550 
Additional records identied
through other sources (n=5)
Records identied through database searching
  (n=3358): 
    Medline/Medline in-process (n=1202) 
    Embase (n=2132) 
    CENTRAL (n=224)
Records aer duplicates removed (n=2734)
Full text articles assessed for eligibility (n=55)
κ=0.88
Randomized controlled trials included (n=4)
Secondary reports with eligible data (n=5)
Records excluded (n=2679)
Full text articles excluded (n=48):
  Observational (n=7)
  Commentary (n=3)
  Secondary report without eligible data
    (n=18)
  Dierent comparison (n=2)
  Duplicate (n=18)
Secondary reports identied
through other means (n=2)
Fig 1 | Prisma flow diagram of studies included in review of transcatheter versus surgical 
aortic valve replacement in patients with severe aortic stenosis at low and intermediate risk
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(21.9%) patients randomized to SAVR died (hazard ratio 
0.86, 95% confidence interval 0.74 to 1.01; I2=37.6%). The 
one month mortality was 3.9% for TAVI and 4.0% for 
SAVR, despite an average predicted risk score of 5.9%.
There was a significant interaction between trans-
femoral TAVI and transapical TAVI (P=0.015; 
 appendix  5). Mortality was lower with transfemoral 
TAVI than with SAVR (hazard ratio 0.79, 95% confidence 
interval 0.66 to 0.94; I2=0%, 30 fewer per 1000 patients, 
moderate certainty; fig 2  and table 2). For transapical 
TAVI, the point estimate suggested harm relative to 
SAVR, but the confidence interval overlapped no effect 
(1.34, 0.91 to 1.97, I2=0%, 57 more per 1000 patients, 
moderate certainty; fig 3  and table 2).
Stroke
The hazard for stroke was lower with TAVI but the con-
fidence interval overlapped no effect (hazard ratio 0.81, 
95% confidence interval 0.63 to 1.01). There was an 
interaction by approach favoring percutaneous retro-
grade TAVI over transapical TAVI (P=0.012; fig 4, appen-
dix 5). The relative risk of stroke compared with SAVR 
was 0.80 (0.63 to 1.01; I2=0%, 20 fewer per 1000 patients, 
moderate certainty; table 2) for transfemoral TAVI and 
1.67 (0.97 to 2.87; I2=0%, 45 more per 1000 patients, 
moderate certainty; table 2) for transapical TAVI.
Acute kidney injury
Acute kidney injury was less common with TAVI (rela-
tive risk 0.48, 95% confidence interval 0.27 to 0.84; 
I2=50%). Heterogeneity was explained by the TAVI 
approach (interaction P<0.001; fig 5 and appendix 5). 
The risk of acute kidney injury for transfemoral TAVI 
compared with SAVR was 0.38 (0.27 to 0.53; I2=0%, 53 
fewer per 1000 patients, high certainty; table 2) and for 
transapical TAVI was 1.54 (0.77 to 3.07; I2=0%, 23 more 
per 1000 patients, low certainty; table 2).
Outcomes favoring tavi
Bleeding
The risk of life threatening or disabling bleeding was 
reduced with TAVI (relative risk 0.39, 95% confidence 
interval 0.35 to 0.45; I2=31%). Bleeding was reduced 
with both transfemoral TAVI (0.39, 0.29 to 0.54; I2=71%, 
252 fewer per 1000 patients, high certainty; table 2) and 
transapical TAVI (0.53, 0.42 to 0.67; I2=0%, 194 fewer per 
1000 patients, high certainty; table 2 ), but significantly 
more so with transfemoral TAVI (P=0.037 for interac-
tion) (fig 6 and appendix 5).
Atrial fibrillation
New onset atrial fibrillation (which includes transient 
perioperative atrial fibrillation) was less common in 
patients randomized to TAVI (three studies, relative risk 
0.43, 95% confidence interval 0.35 to 0.52; I2=38%, 178 
fewer per 1000 patients, high certainty (table 2 and fig B 
in appendix 6).
Recovery time
Three trials reported length of index admission to hos-
pital: patients in the TAVI group in the two larger t
ab
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studies (n=2308) were in hospital for about three and 
four fewer days than the SAVR group (both about 33% 
shorter and P≤0.001).8 28  We could not pool data 
because one randomized controlled trial did not report 
standard deviations.8  There was no significant 
 difference in the smallest STACCATO trial, but numbers 
were not reported.27
Pain
No studies reported on pain after the intervention.
Outcomes favoring savr
Symptoms of heart failure
The TAVI group had higher odds of having 1 point worse 
symptoms of heart failure on the NYHA scale than the 
SAVR group (odds ratio 1.29, 95% confidence interval 
1.08 to 1.55 (ordinal regression); I2=0%; fig C in appen-
dix 6). For every 1000 patients, 59 (17 to 103) more 
patients experienced any symptoms of heart failure, of 
which 18 (5 to 34) were NYHA class III or IV (moderate 
certainty; table 2). The proportional odds assumption 
was not violated for any study.
Aortic valve reintervention
Aortic valve reinterventions occurred more often in the 
TAVI group at a median of two years (relative risk 3.25, 
95% confidence interval 1.29 to 8.14; I2=0%, 7 more per 
1000 patients, moderate certainty; table 2 and fig D in 
appendix 6).
Insertion of permanent pacemaker
Permanent pacemaker insertion was more common 
with TAVI than SAVR (relative risk 2.45, 95% confidence 
interval 1.17 to 5.14; I2=88%, 134 more per 1000 patients, 
moderate certainty; table 2  and fig 7).
Moderate or severe aortic valve regurgitation
Aortic valve regurgitation of at least moderate severity 
was more common in the TAVI group than in the SAVR 
group (three randomized controlled trials, relative 
risk 12.22, 95% confidence interval 5.17 to 28.88; 
I2=0%, 80 more per 1000 patients, high certainty; 
fig E in appendix 6).
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Fig 4 | Forest plot for relative risk of stroke at longest follow-up for transcatheter aortic valve implantation (tavi) compared 
with surgical aortic valve replacement (savr) for severe aortic stenosis, by valve approach. P=0.012 for interaction
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Fig 2 | Kaplan-meier survival curve for transfemoral 
transcatheter aortic valve implantation (tavi) versus 
surgical aortic valve replacement (savr) for severe aortic 
stenosis. nOtiOn and Partner 2a provided data to 24 
months, and us Pivotal provided data to 36 months
MonthsNo at risk
SAVR
TAVI
Su
rv
iv
or
s (
%
)
0 3 6 9 12
Hazard ratio
1.34 (0.91 to 1.97)
15 18 21 24
282
269
192
198
180
183
172
173
163
168
0
20
40
60
80
100
SAVR TAVI
Fig 3 | Kaplan-meier survival curve for transapical 
transcatheter aortic valve implantation (tavi) versus 
surgical aortic valve replacement (savr) for severe aortic 
stenosis. staCCatO provided data to 3 months, and 
Partner 2a provided data to 24 months
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Outcomes similar between groups
Myocardial infarction
There was no detectable difference in myocardial 
infarction between TAVI and SAVR (relative risk 0.87, 
95% confidence interval 0.58 to 1.29; I2=0%, 5 fewer per 
1000 patients, moderate certainty; table 2 and fig F in 
appendix 6).
Health related quality of life (HRQoL)
Only the US Pivotal26  and STACCATO27  trials reported 
HRQoL. The PARTNER 2A study protocol included 
HRQoL, but the primary publication did not include 
these data.8  The US Pivotal trial found an improvement 
between groups that was important to patients in over-
all HRQoL at one month in the TAVI group, but there 
was no difference with SAVR at six months and up to 
two years.29 30  The STACCATO trial found no differences 
between groups in HRQoL at three months.27
sensitivity and other subgroup analyses
The STACCATO trial was stopped early and was the only 
study to exclusively use a transapical approach.27 
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Fig 5 | Forest plot for relative risk of acute kidney injury at longest follow-up for transcatheter aortic valve implantation 
(tavi) compared with surgical aortic valve replacement (savr) for severe aortic stenosis, by valve approach. P<0.001 for 
interaction
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Fig 6 | Forest plot for relative risk of life threatening or disabling bleeding at longest follow-up for transcatheter aortic 
valve implantation (tavi) compared with surgical aortic valve replacement (savr) for severe aortic stenosis, by valve 
approach. P=0.037 for interaction
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Fig 7 | Forest plot for permanent pacemaker insertion at longest follow-up for transcatheter aortic valve implantation 
(tavi) compared with surgical aortic valve replacement (savr) for severe aortic stenosis
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 Sensitivity analyses without STACCATO did not change 
statistical or clinical interpretation for any outcome.
As the included studies otherwise had similar risks of 
bias, subgroup analyses by risk of bias were not possi-
ble. Results at one year were similar to those at longest 
follow-up (appendix 7). There were no credible sub-
group differences between balloon expandable and self 
expanding valves or between trials enrolling patients at 
higher or lower perioperative risk (appendix 5).
discussion
This review shows that in patients with severe aortic 
stenosis, for several outcomes, transfemoral TAVI 
results in better outcomes relative to SAVR than the 
transapical approach relative to SAVR; this was true for 
mortality, stroke, acute kidney injury, and bleeding. 
These subgroup effects are highly credible. They are 
among a small number of a priori hypotheses with a 
prespecified direction, including a comparison within 
studies,8  chance is an unlikely explanation, and the 
effect is consistent across these related outcomes.34
Mortality was reduced with transfemoral TAVI com-
pared with SAVR by about 3%, stroke by 2%, acute kid-
ney injury by 5%, bleeding by 24%, new onset atrial 
fibrillation by 18%, and duration of index admission by 
three days. These benefits, however, come with associ-
ated harms. TAVI was associated with an increased risk 
of experiencing symptoms of heart failure by about 6% 
(2% of which were moderate or severe), permanent 
pacemaker insertion by about 15%, and aortic valve 
reintervention over the short term by about 1%.
The picture is quite different with transapical TAVI, 
which, though it probably shares benefits of less bleed-
ing, less atrial fibrillation, and shorter hospital stay, 
increased the risk of stroke compared with SAVR by 
about 5% and could also increase mortality.
strength and limitations
Strengths of this review include a comprehensive 
search for evidence; duplicate assessment of eligibility, 
risk of bias, and data abstraction; and assessments of 
risk of bias that included addressing loss to follow-up 
across studies (and found results robust to loss to fol-
low-up).23 The review included rigorous assessment of 
the quality of evidence (and found the quality for many 
critical outcomes high and others moderate) and of the 
credibility of subgroup analyses (with crucial differ-
ences between transfemoral and transapical TAVR 
approaches). We have presented absolute and relative 
risks, which are crucial for making decisions between 
TAVI and SAVR.
Limitations include a modest total number of 
patients (3179) and questionable generalization of 
results to low risk patients (most patients were at 
 intermediate rather than low surgical risk). The ran-
domized controlled trials used bioprosthetic valves, 
typically used in older patients, in all SAVRs.5 6  Our 
results therefore apply only to patients who have 
already chosen to use a bioprosthetic valve instead of a 
mechanical valve. No trial reported recovery time—
beyond length of hospital stay—or pain after the 
 intervention, two outcomes that our patient representa-
tives identified as important. The incidence of chronic 
pain after sternotomy is about 28% and 13% for any and 
moderate pain at one year, respectively, suggesting that 
chronic pain might be less common in TAVI.35  An unad-
justed observational study that included both TAVI and 
SAVR patients, however, showed no difference in pain 
scores at three months.36  We are not able to ascertain 
how much of the increased risk of atrial fibrillation with 
SAVR represents transient postoperative atrial fibrilla-
tion—less important for patients than persistent atrial 
fibrillation. Further, we did not find a subgroup effect 
by type of TAVI valve on pacemaker insertion and thus 
present a single estimate of effect. We note, however, 
that there is evidence external to this review that self 
expanding valves impart a higher risk of need for pace-
maker insertion than balloon expanding valves.37  Tech-
nology for TAVI38 39  and SAVR40 is continually changing, 
potentially further increasing the attractiveness of the 
TAVI option.
The most important limitation is that the relatively 
short duration of follow-up leaves uncertainty about 
one critical outcome: the need for reintervention over 
the longer term, a major concern with TAVI valves. We 
did find that TAVI is associated with a higher risk of aor-
tic valve reintervention, although we were not able to 
determine whether this was because of paravalvular 
regurgitation or structural valve degeneration, and the 
absolute risk was low. The younger the patient, the 
greater the extent to which the uncertainty regarding 
the long term durability of TAVI valves is likely to influ-
ence the decision between TAVI and SAVR.
Our findings are consistent with those from recently 
published meta-analyses for many outcomes,9 10 but we 
have also provided absolute as well as relative risks and 
a formal rating of the quality of the evidence and docu-
mented the credibility of the crucial outcome differ-
ences between transfemoral and transapical TAVI 
approaches. Further, we quantified several new find-
ings, including an increased risk of aortic valve reinter-
vention, an increased risk of symptoms of heart failure 
with TAVI, and an increased risk of life threatening or 
disabling bleeding (rather than major bleeding, which 
is less important to patients) with SAVR.
In conclusion, we have clarified the trade-offs 
between TAVI and SAVR and identified issues of resid-
ual uncertainty. For patients with lower life expectancy 
(such as those aged over 85), in whom longer term valve 
deterioration is likely to be less of an issue, the benefits 
of transfemoral TAVI versus SAVR on mortality, stroke, 
life threatening or disabling bleeding, and a less inva-
sive procedure are compelling. Younger patients (such 
as those aged 65-85), who are less concerned about the 
limited evidence regarding valve deterioration and the 
necessity for a second procedure, might (or might not) 
also find these mortality and morbidity benefits com-
pelling. Even younger patients (such as those aged 
under 65), for whom valve longevity could be extremely 
important, are more likely to choose SAVR over TAVI or 
even to choose a mechanical over a bioprosthetic valve. 
Finally, patients in whom a transfemoral TAVI approach 
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is not feasible are unlikely to view the transapical 
approach, which is associated with a higher rate of 
stroke and a possibly higher mortality rate than SAVR, 
as an attractive option.
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